A Randomized Phase 2 Study of VT-1161 for the Treatment of Acute Vulvovaginal Candidiasis

BACKGROUND: Acute vulvovaginal candidiasis (VVC) is common among women, but current azole antifungal treatments are often associated with safety and resistance issues. VT-1161 (oteseconazole) is an oral agent with increased selectivity for fungal CYP51. In this phase 2 clinical study, we evaluated t...

Descripción completa

Detalles Bibliográficos
Autores principales: Brand, Stephen R, Sobel, Jack D, Nyirjesy, Paul, Ghannoum, Mahmoud A, Schotzinger, Robert J, Degenhardt, Thorsten P
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2020
Materias:
Online Only Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8492116/
https://www.ncbi.nlm.nih.gov/pubmed/32818963
http://dx.doi.org/10.1093/cid/ciaa1204

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8492116/
https://www.ncbi.nlm.nih.gov/pubmed/32818963
http://dx.doi.org/10.1093/cid/ciaa1204

Ejemplares similares